Pancreatic carcinoma cell killing via adenoviral mediated delivery of the herpes simplex virus thymidine kinase gene

被引:40
作者
Rosenfeld, ME
Vickers, SM
Raben, D
Wang, MH
Sampson, L
Feng, MZ
Jaffee, E
Curiel, DT
机构
[1] UNIV ALABAMA,GENE THERAPY PROGRAM,BIRMINGHAM,AL 35294
[2] UNIV ALABAMA,MED GENET PROGRAM,BIRMINGHAM,AL 35294
[3] UNIV ALABAMA,DEPT SURG,BIRMINGHAM,AL 35294
[4] UNIV ALABAMA,DEPT RADIAT ONCOL,BIRMINGHAM,AL 35294
[5] JOHNS HOPKINS UNIV,DEPT ONCOL,BALTIMORE,MD
关键词
D O I
10.1097/00000658-199705000-00017
中图分类号
R61 [外科手术学];
学科分类号
摘要
Objective Use of adenoviral mediated delivery of the herpes simplex virus thymidine kinase (HSV-TK) gene as a gene therapy strategy for carcinoma of the pancreas. Summary Background Data Expression of HSV-TK selectively sensitizes cells to the nucleoside analog ganciclovir (GCV). This strategy has been used to treat other compartmentalized tumor models. Therefore, the containment of pancreatic carcinoma makes it amenable to this gene therapy approach. Methods A recombinant adenoviral vector encoding the HSV-TK gene was used to induce GCV sensitivity and test the potential bystander effect in established pancreatic carcinoma cell lines and patient-derived tumor material. Additionally, Balb/C nude mice were injected intraperitoneally with human pancreatic carcinoma cells and treated with GCV (50 mg/kg per day) for 14 days. Results Expression of the HSV-TK gene elicited a significant bystander effect in the presence of GCV. Pancreatic tumor cells injected intraperitoneally into nude mice resulted in significant tumor formation. Treatment of animals with AdCMVHSV-TK and GCV induced a dramatic decrease in overall tumor burden for up to 8 weeks post-GCV treatment. Conclusions Pancreatic carcinoma cells are highly susceptible to transduction with recombinant adenoviral vectors and elicit a potent bystander effect on neighboring tumor cells. Additionally, in vivo treatment of tumor-bearing animals results in dramatic reduction of overall tumor burden, thus providing the rationale for molecular chemotherapy of pancreatic carcinoma.
引用
收藏
页码:609 / 618
页数:10
相关论文
共 42 条
  • [1] ABE A, 1993, P SOC EXP BIOL MED, V203, P354
  • [2] AOKI K, 1995, CANCER RES, V55, P3810
  • [3] BASS C, 1995, CANCER GENE THER, V2, P97
  • [4] BECKER TC, 1994, METHOD CELL BIOL, V43, P161
  • [5] IN-VITRO EVIDENCE THAT METABOLIC COOPERATION IS RESPONSIBLE FOR THE BYSTANDER EFFECT OBSERVED WITH HSV TK RETROVIRAL GENE-THERAPY
    BI, WL
    PARYSEK, LM
    WARNICK, R
    STAMBROOK, PJ
    [J]. HUMAN GENE THERAPY, 1993, 4 (06) : 725 - 731
  • [6] CANCER STATISTICS, 1993
    BORING, CC
    SQUIRES, TS
    TONG, T
    [J]. CA-A CANCER JOURNAL FOR CLINICIANS, 1993, 43 (01) : 7 - 26
  • [7] FREQUENT SOMATIC MUTATIONS AND HOMOZYGOUS DELETIONS OF THE P16 (MTS1) GENE IN PANCREATIC ADENOCARCINOMA
    CALDAS, C
    HAHN, SA
    DACOSTA, LT
    REDSTON, MS
    SCHUTTE, M
    SEYMOUR, AB
    WEINSTEIN, CL
    HRUBAN, RH
    YEO, CJ
    KERN, SE
    [J]. NATURE GENETICS, 1994, 8 (01) : 27 - 32
  • [8] INVIVO GENE-TRANSFER WITH RETROVIRAL VECTOR PRODUCER CELLS FOR TREATMENT OF EXPERIMENTAL BRAIN-TUMORS
    CULVER, KW
    RAM, Z
    WALLBRIDGE, S
    ISHII, H
    OLDFIELD, EH
    BLAESE, RM
    [J]. SCIENCE, 1992, 256 (5063) : 1550 - 1552
  • [9] DIMAIO JM, 1994, SURGERY, V116, P205
  • [10] SELECTIVITY OF ACTION OF AN ANTI-HERPETIC AGENT, 9-(2-HYDROXYETHOXYMETHYL)GUANINE
    ELION, GB
    FURMAN, PA
    FYFE, JA
    DEMIRANDA, P
    BEAUCHAMP, L
    SCHAEFFER, HJ
    [J]. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1977, 74 (12) : 5716 - 5720